US Patent Issued to The United States of America, as represented by the Secretary, Department of Health and Human Services on May 20 for "HLA class II-restricted t cell receptors against mutated RAS" (American, Israeli Inventors)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,304,940, issued on May 20, was assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services (Bethesda, Md.).

"HLA class II-restricted t cell receptors against mutated RAS" was invented by Gal Cafri (Kibbutz Nir David, Israel), Paul F. Robbins (Chevy Chase, Md.) and Steven A. Rosenberg (Potomac, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and protein...